A three-year agreement has been struck between Albany Molecular Research Inc. (AMRI) and the New York Center for Nanomedicine Research (NYCNMR) to co-market their joint nanotechnology innovations and services to a range of global clients and enhancing nanotechnology application in an integrated discovery setting.

“We are very enthusiastic about our collaboration with NYCNMR as it represents a unique opportunity to provide drug discovery customers with cutting-edge nanotechnologies and an environment that can create preventative, diagnostic and therapeutic approaches to treat a variety of human diseases,” said Rory Curtis, Ph.D., vice president of discovery biology and pharmacology and AMRI Buffalo site head.

NYCNMR is based on the University of Buffalo’s Clinical and Translational Research Center and currently collaborates with a number of pharmaceutical companies and academic research groups to promote integration of cutting-edge nanotechnology and medical research in the fields of medicine, advanced nanoparticle development, targeted delivery systems for drugs and biologics, and transfection and transport platforms.

The partnership with AMRI is expected to benefit the organizations as follows: When AMRI is able to access NYCNMR’s therapeutic and formulation services, NYCNMR’s customers will benefit from  AMRI’s diverse range of drug discovery solutions, which include assay method development, high-throughput screening, high-content screening, hit-to-lead-medicinal chemistry, computer-aided drug discovery, in vitro biology and pharmacology , DMPK assays, and ASCC small molecule an natural products collections.

This agreement follows the acquisitions by AMRI of several firms in 2015, including a $174 million deal for Gadea Pharmaceutical Group.

“The agreement between AMRI and NYCNMR represents the continued realization of Governor Andrew Cuomo's vision for the Buffalo Medical Innovation and Commercialization Hub (BMIC) to build upon Western New York's leadership in life sciences research and enable the commercialization of innovations developed there,” said Tom O'Brien, associate vice president for innovation infrastructure and resources for SUNY Polytechnic Institute, which manages the BMIC.

Previous articleCepheid, MedImmune Join COMBACTE in Antibacterial Diagnostics Collaboration
Next articleEnzyme’s 3D Pose Could Improve Antibiotic Drug Discovery